LLY

1,063.79

-1.23%↓

JNJ

222.81

-0.32%↓

ABBV

215.58

+1.54%↑

UNH

377.18

-0.59%↓

MRK

115.96

+0.86%↑

LLY

1,063.79

-1.23%↓

JNJ

222.81

-0.32%↓

ABBV

215.58

+1.54%↑

UNH

377.18

-0.59%↓

MRK

115.96

+0.86%↑

LLY

1,063.79

-1.23%↓

JNJ

222.81

-0.32%↓

ABBV

215.58

+1.54%↑

UNH

377.18

-0.59%↓

MRK

115.96

+0.86%↑

LLY

1,063.79

-1.23%↓

JNJ

222.81

-0.32%↓

ABBV

215.58

+1.54%↑

UNH

377.18

-0.59%↓

MRK

115.96

+0.86%↑

LLY

1,063.79

-1.23%↓

JNJ

222.81

-0.32%↓

ABBV

215.58

+1.54%↑

UNH

377.18

-0.59%↓

MRK

115.96

+0.86%↑

Home・Lista de Ações・Halozyme Therapeutics Inc

Halozyme Therapeutics Inc

Fechado

SetorSaúde

66.19 -2.95

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

65.3

Máximo

68.18

Indicadores-chave
By Trading Economics
Rendimento	292M 150M
Vendas	-75M 377M
P/E Médio do Setor	24.112 50.102
EPS	1.221
Margem de lucro	39.832
Funcionários	423
EBITDA	-63M 218M

Recomendações
By TipRanks
Recomendações	Comprar
Previsão para 12 meses	+25.92% upside

Dividendos
By Dow Jones
Próximos Ganhos	4 de ago. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	501M 8.2B
Abertura anterior	69.14
Fecho anterior	66.19

Halozyme Therapeutics Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

2 de jun. de 2026, 20:30 UTC

Ganhos

Palo Alto Networks 3Q Revenue Rises as Customers Beef Up Cyber Defenses

3 de jun. de 2026, 00:00 UTC

Aquisições, Fusões, Aquisições de Empresas

Garth Brooks Considers Sale of Music Catalog, Seeking Roughly $2 Billion -- WSJ

3 de jun. de 2026, 00:00 UTC

Aquisições, Fusões, Aquisições de Empresas

Brooks Had Been Entertaining a Deal for a Few Years, Sources Say -- WSJ

3 de jun. de 2026, 00:00 UTC

Aquisições, Fusões, Aquisições de Empresas

Brooks Seeking About $2 Billion for Rights to Songs, Recordings, Sources Say -- WSJ

3 de jun. de 2026, 00:00 UTC

Aquisições, Fusões, Aquisições de Empresas

Garth Brooks Considering Sale of Music Catalog, Sources Say -- WSJ

2 de jun. de 2026, 23:58 UTC

Conversa de Mercado

Australia's Consumer Sector Expected to Be Stung by Housing Downturn -- Market Talk

2 de jun. de 2026, 23:46 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

2 de jun. de 2026, 23:46 UTC

Conversa de Mercado

Nikkei May Rise as AI Demand Hopes Continue -- Market Talk

2 de jun. de 2026, 23:41 UTC

Conversa de Mercado

Oil Rises Amid Signs of U.S.-Iran Peace Talks Stalling -- Market Talk

2 de jun. de 2026, 23:01 UTC

Aquisições, Fusões, Aquisições de Empresas

ACCC Says Owner of Metro Petroleum Brand to Buy the 41 Sites

2 de jun. de 2026, 23:01 UTC

Aquisições, Fusões, Aquisições de Empresas

ACCC Says Ampol Must Sell 41 Retail Fuel Sites to an Approved Purchaser

2 de jun. de 2026, 23:00 UTC

Aquisições, Fusões, Aquisições de Empresas

Australia's Competition Regulator Approves Ampol's Purchase of EG Australia With Conditions

2 de jun. de 2026, 22:57 UTC

Conversa de Mercado

Australian Dollar Could Fall Following 1Q GDP Data -- Market Talk

2 de jun. de 2026, 22:50 UTC

Conversa de Mercado

Ulta Beauty Says TikTok Shop Will Provide 'Halo' Effect -- Market Talk

2 de jun. de 2026, 21:07 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

2 de jun. de 2026, 21:07 UTC

Conversa de Mercado

Tokenized Assets Need Access to Digital-Finance Plumbing -- Market Talk

2 de jun. de 2026, 21:00 UTC

Ganhos

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2 de jun. de 2026, 20:50 UTC

Conversa de Mercado

Financial Services Roundup: Market Talk

2 de jun. de 2026, 20:46 UTC

Ganhos

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2 de jun. de 2026, 20:38 UTC

Ganhos

GitLab Stock Rises as the Software Company Raises Guidance on AI Business Momentum -- Barrons.com

2 de jun. de 2026, 20:21 UTC

Ganhos

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2 de jun. de 2026, 20:12 UTC

Ganhos

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2 de jun. de 2026, 20:05 UTC

Ganhos

Palo Alto Networks 3Q Product Rev $594M

2 de jun. de 2026, 20:05 UTC

Ganhos

Palo Alto Networks Sees FY26 Next-Generation Security ARR $8.9B-$8.95B

2 de jun. de 2026, 20:05 UTC

Ganhos

Palo Alto Networks Raises FY26 View To Adj EPS $3.77-Adj EPS $3.79 >PANW

2 de jun. de 2026, 20:05 UTC

Ganhos

Palo Alto Networks 3Q Subscription and Support Rev $2.41B

2 de jun. de 2026, 20:05 UTC

Ganhos

Palo Alto Networks Sees FY26 Remaining Performance Obligation $20.9B-$21B

2 de jun. de 2026, 20:05 UTC

Ganhos

Palo Alto Networks Sees 4Q Rev $3.345B-$3.355B >PANW

2 de jun. de 2026, 20:05 UTC

Ganhos

Palo Alto Networks Sees 4Q Adj EPS 96c-Adj EPS 98c >PANW

2 de jun. de 2026, 20:05 UTC

Ganhos

Palo Alto Networks on Track to Achieve 40% Adj Free Cash Flow Margin in FY28

Comparação entre Pares

Variação de preço

Halozyme Therapeutics Inc Previsão

Preço-alvo

By TipRanks

25.92% parte superior

Previsão para 12 meses

Média 85.8 USD 25.92%

Máximo 96 USD

Mínimo 70 USD

Com base em 5 analistas de Wall Street que oferecem metas de preço de 12 meses para Halozyme Therapeutics Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

5 ratings

Comprar

Manter

Vender

Com base em 5 analistas que deram avaliações de ações para Halozyme Therapeutics Inc - Dist nos últimos 3 meses.

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre Halozyme Therapeutics Inc

Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.